4C Medical is a Minnesota-based developer of AltaValve, a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process.
4C Medical will now pay an additional $US1 million ($US 0.44 million previously received) to use the technology to sterilise the ADAPT tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve system device.
“Transformative healing advantages” of ADAPT
The 4C Medical implant utilises tissue processed by Admedus’ clinically superior ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.
4C Medical will benefit from this technology to optimise function and durability.
Admedus chief executive officer Wayne Paterson said: “For the millions of patients suffering from Mitral Regurgitation, Admedus is proud to provide the transformative healing advantages of ADAPT treated tissue with demonstrated clinically superior performance over ten years.”